drugset / Trial / NCT05686564
Early Access Program for ALXN1840 in Patients With Wilson Disease
Summary
This is an open-label, single-arm, multi-center EAP, designed to provide early access to ALXN1840 for eligible patients with WD.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TIOMOLIBDATE CHOLINE | Small molecule | — | — |